DE602005016831D1 - - Google Patents

Info

Publication number
DE602005016831D1
DE602005016831D1 DE602005016831T DE602005016831T DE602005016831D1 DE 602005016831 D1 DE602005016831 D1 DE 602005016831D1 DE 602005016831 T DE602005016831 T DE 602005016831T DE 602005016831 T DE602005016831 T DE 602005016831T DE 602005016831 D1 DE602005016831 D1 DE 602005016831D1
Authority
DE
Germany
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005016831T
Other languages
German (de)
Inventor
Yasuharu Nishimura
Tetsuya Nakatsura
Yoshiaki Ikuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kumamoto University NUC
Original Assignee
Kumamoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kumamoto University NUC filed Critical Kumamoto University NUC
Publication of DE602005016831D1 publication Critical patent/DE602005016831D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE602005016831T 2004-10-19 2005-08-09 Expired - Lifetime DE602005016831D1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004303688 2004-10-19
PCT/JP2005/014567 WO2006043362A1 (ja) 2004-10-19 2005-08-09 悪性黒色腫（メラノーマ）の新規な診断キット

Publications (1)

Publication Number Publication Date
DE602005016831D1 true DE602005016831D1 (https=) 2009-11-05

Family

ID=36202786

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005016831T Expired - Lifetime DE602005016831D1 (https=) 2004-10-19 2005-08-09

Country Status (6)

Country Link
US (1) US8017345B2 (https=)
EP (1) EP1813943B1 (https=)
JP (1) JP4834839B2 (https=)
AU (1) AU2005297303B2 (https=)
DE (1) DE602005016831D1 (https=)
WO (1) WO2006043362A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373055T3 (es) 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
AU2007259667B2 (en) * 2006-06-16 2012-06-14 Oncotherapy Science, Inc. SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
BRPI0923155A2 (pt) * 2008-12-05 2018-10-23 Abraxis Bioscience Llc scfcs de ligação a sparc
AU2010295324B2 (en) * 2009-09-18 2015-04-30 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
WO2011137114A1 (en) * 2010-04-26 2011-11-03 Abraxis Bioscience, Llc Sparc binding antibodies and uses thereof
MX2012013874A (es) 2010-06-03 2013-01-24 Abraxis Bioscience Llc Uso de la signatura en el microentorno de sparc en el tratamiento de cancer.
US20130281376A1 (en) * 2010-10-08 2013-10-24 Abraxis Bioscience, Llc Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
EP2863224A4 (en) * 2012-06-18 2016-05-04 Nat Cancer Ct KIT FOR DIAGNOSIS MALIGNER MELANOME
US20140314697A1 (en) * 2013-04-18 2014-10-23 Corum Inc. Method for Inhibiting Inflammation and Reducing Melanophilin Expression with Glycine Derivatives And the Composition Thereof
US20150005184A1 (en) * 2013-06-28 2015-01-01 Dermtech International Diagnosis of melanoma by nucleic acid analysis
CA3090785A1 (en) 2018-02-14 2019-08-22 John Daniel Dobak Iii Novel gene classifiers and uses thereof in non-melanoma skin cancers
JP2022524641A (ja) 2019-03-26 2022-05-09 ダームテック，インク． 皮膚癌における新規な遺伝子分類子とその使用
US12576166B2 (en) 2020-07-27 2026-03-17 Board Of Regents, The University Of Texas System Contrast agents for detection of enzyme activities based on melanin synthesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064626A2 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
AU2003281325A1 (en) * 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
WO2004020624A1 (ja) * 2002-08-30 2004-03-11 Kumamoto Technology & Industry Foundation 癌抗原及びその利用
AU2004260083B2 (en) * 2003-07-17 2011-04-07 Pacific Edge Limited Markers for detection of gastric cancer
EP1684076B1 (en) * 2003-10-29 2008-12-31 Kumamoto Technology & Industry Foundation Diagnostic method for malignant melanoma

Also Published As

Publication number Publication date
JPWO2006043362A1 (ja) 2008-05-22
EP1813943B1 (en) 2009-09-23
AU2005297303B2 (en) 2011-11-10
JP4834839B2 (ja) 2011-12-14
AU2005297303A1 (en) 2006-04-27
US20090111095A1 (en) 2009-04-30
US8017345B2 (en) 2011-09-13
EP1813943A1 (en) 2007-08-01
EP1813943A4 (en) 2007-12-12
WO2006043362A1 (ja) 2006-04-27

Similar Documents

Publication Publication Date Title
BE2024C508I2 (https=)
BE2023C542I2 (https=)
BE2022C549I2 (https=)
BE2021C001I2 (https=)
BE2020C513I2 (https=)
BE2020C517I2 (https=)
BE2019C540I2 (https=)
BE2019C523I2 (https=)
BE2019C548I2 (https=)
BE2019C506I2 (https=)
BE2020C525I2 (https=)
BE2018C045I2 (https=)
BE2017C063I2 (https=)
BE2017C027I2 (https=)
BE2017C023I2 (https=)
BE2017C002I2 (https=)
BE2016C067I2 (https=)
BE2016C014I2 (https=)
BE2015C041I2 (https=)
BE2015C038I2 (https=)
BE2013C071I2 (https=)
BE2015C066I2 (https=)
BE2012C025I2 (https=)
BE2015C065I2 (https=)
BE2019C535I2 (https=)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition